Influenza Vaccination During Coronavirus Disease 2019 Outbreak After Acute Coronary Syndrome and Chronic Heart Failure (IV-ACS&CHF)

  • STATUS
    Recruiting
  • End date
    May 31, 2023
  • participants needed
    200
  • sponsor
    Samara Regional Cardiology Dispensary
Updated on 23 March 2022
myocardial infarction
unstable angina
infarct
acute coronary syndrome

Summary

Study Description:

Background: Well-known fact that the number of cardiovascular diseases is on the rise during influenza epidemic. It is conceivable that influenza may precipitate plaque rupture, increase cytokines with central roles in plaque destabilization and trigger the coagulation cascade. A number of studies have shown that the risk of cardiovascular complications (ACS, stroke, CHF decompensation, cardiac arrhythmias) seem to be reduced following influenza vaccination. The Influenza Vaccination After Myocardial Infarction study data published in September 2021 have demonstrated a significant decrease of mortality (by 40%) during 1 year of follow-up in patients with myocardial infarction (MI) who has been vaccinated during the first 72 hours.

Objective: the objective is to find out whether influenza vaccination protects against cardiovascular events and death in ACS & CHF patients vaccinated during hospitalization Methods: Population: 400 patients aged 65 and older with acute coronary syndrome are randomized 1:1 and followed up via telephone calls and registries (AIS "Mortality").

Patients will be included in the study in cardiology departments № 1, 2, 3, 5, 6 of the State Budgetary Healthcare Institution "Samara Regional Clinical Cardiology Dispensary named after V.P. Polyakov" Intervention: Influenza vaccination. Control: group of unvaccinated patients. Planned study period is 1 year.

Description

Detailed Description:

Name of investigational treatment: Influenza vaccine ("Ultrix Quadri"™) Planned study period: October - December 2021 ((influenza season) Long-term follow up to 365 days from the moment of vaccination of the last included patient (approximately November-December 2022) via phone calls.

Methodology: vaccination will be start after informed consent on the day of leaving hospital with "Ultrix Quadri"™ vaccine Intervention Model: Parallel Assignment Number of subjects: 400 Number of vaccinated patients is 200 Number of patients with placebo is 200 Primary endpoint: сomposite of all-cause death, MI, or stent thrombosis at 12 months Secondary endpoints

  • The number of participants with all-cause death till 1 year (key secondary outcome)
  • The number of participants with myocardial infarction till 1 year (key secondary outcome)
  • The number of participants with stent thrombosis till 1 year (key secondary outcome)
  • The number of participants with cardiovascular death till 1 year (key secondary outcome)
  • The number of participants with a new revascularization till 1 year
  • The number of participants with cardiovascular death, a new myocardial infarction or stent thrombosis (first occurring) till 1 year
  • The number of participants with stroke, including transient ischemic attack (TIA) till 1 year
  • The number of participants with hospitalization for heart failure till 1 year
  • The number of participants with hospitalization for arrhythmia till 1 year
  • Safety of vaccination (incidence of side effects)

Follow up by telephone and registry information (AIS "Mortality"): the follow up for endpoints will be performed using telephone contacts with the patients or first degree relatives.

Purpose of phone calls:

  • to assess the safety of vaccination the day after vaccination (T1) 7 (± 1) day after vaccination (T2)
  • to study the effectiveness 365 (± 5) days after vaccination (T3)

Reporting for adverse events: The patients will be informed to contact the investigator or study nurse if any adverse event should occur during this timeframe.

Study Start Date: September 2021 Actual Primary Completion Date (safety assessment): December 2021 Actual Study Completion Date (efficiency mark): December 2022 Experimental Drug: influenza vaccine Ultrix Quadri Standard influenza vaccine administered as a deep subcutaneous injection at one occasion per subject.

The experimental drug is not administered to patients in the control group.

Eligibility Criteria:

Ages Eligible for Study: 65 Years and older (Adult, Older Adult) Sexes Eligible for Study: All

Inclusion Criteria:

  • Patients with a diagnosis of ACS with transformation to acute MI or unstable angina Patients with a diagnosis of Chronic Heart Failure due to different reasons
  • Written informed consent.

Exclusion Criteria:

  • Influenza vaccination during the current influenza season or anticipating to be vaccinated during the current influenza season.
  • Coronavirus disease 2019 vaccination during 30 days
  • Indication for influenza vaccination for some indication other than myocardial infarction.
  • Severe allergy to eggs or previous allergic reaction to influence vaccine.
  • Suspicion of febrile illness or acute, ongoing infection.
  • Hypersensitivity to the active substances or ingredients of Ultrix Quadri or against any residues, such as eggs (ovalbumin or chicken proteins), neomycin, formaldehyde and octoxinol.
  • Subjects with endogenic or iatrogenic immunosuppression that may result in reduced immunization response.
  • Inability to provide informed consent.
  • Age below 65 years.

Details
Condition Acute Coronary Syndrome, Chronic Heart Failure
Treatment Ultrix Quadri
Clinical Study IdentifierNCT05232292
SponsorSamara Regional Cardiology Dispensary
Last Modified on23 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with a diagnosis of ACS with transformation to AMI or unstable angina
Patients with a diagnosis of CHF Written informed consent

Exclusion Criteria

• Influenza vaccination during the current influenza season or anticipating to be vaccinated during the current influenza season
COVID-19 vaccination during 30 days
Indication for influenza vaccination for some indication other than myocardial infarction
Severe allergy to eggs or previous allergic reaction to influence vaccine
Suspicion of febrile illness or acute, ongoing infection
Hypersensitivity to the active substances or ingredients of Ultrix Quadri or against any residues, such as eggs (ovalbumin or chicken proteins), neomycin, formaldehyde and octoxinol
Subjects with endogenic or iatrogenic immunosuppression that may result in reduced immunization response
Inability to provide informed consent
Age below 65 years
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note